Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Feasibility and Effects of a Realistic Stressful Virtual Environment on Balance and Mobility in Healthy Adults: A Pilot Study

5. november 2026 oppdatert av: Vrije Universiteit Brussel

Does a Real-life Stressful Virtual Environment Change Balance and Mobility Performance? A Pilot Feasibility Study

The goal of this pilot clinical trial is to evaluate the feasibility of a new approach to assessing balance and mobility in everyday situations by performing established clinical tests in a stressful virtual reality environment. The study involves healthy adults aged 18 years and older with no self-reported neurological disorders or history of epilepsy.

The main questions it aims to answer are:

  1. Is it feasible to perform standard balance and mobility tests in a virtual reality environment simulating a busy train station?
  2. How does this virtual environment affect participants' balance and mobility test performance?
  3. How do participants experience the virtual environment, including their sense of being there and any discomfort or virtual reality sickness?

Researchers will compare each participant's performance with and without virtual reality to see if the virtual environment changes balance and mobility test results.

Participants will:

  • Spend a brief familiarisation period in the virtual environment before testing.
  • Complete the Mini-BESTest, which assesses balance through a series of tasks, with and without virtual reality.
  • Complete the Timed Up and Go test, which involves standing up from a chair, walking three meters, turning, returning, and sitting down, with and without virtual reality and with and without counting backwards by threes.
  • Complete the 10-Meter Walk Test at comfortable and fast walking speeds, with and without virtual reality.
  • Complete questionnaires after the final virtual reality exposure about their sense of being in the virtual environment and any symptoms of discomfort or sickness.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

11

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • healthy adults aged 18 years and older

Exclusion Criteria:

  • self-reported neurological disorders
  • history of epilepsy

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Balance and mobility assessment with and without virtual reality

All participants complete the Mini-BESTest, Timed Up and Go test, and 10-Meter Walk Test both without a virtual reality headset and while wearing a headset displaying a busy virtual train station. The Timed Up and Go test is performed with and without an additional cognitive task in each condition.

Participants wear a standalone virtual reality headset (Meta Quest 3) displaying a busy train-station environment while completing standard balance and mobility assessments. The environment includes moving pedestrians, animated displays, and recorded train-station sounds. Participants undergo a brief familiarisation period before testing.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of participants completing all planned assessments
Tidsramme: At the end of the single assessment session on Day 1, after completion or discontinuation of the planned assessments.

Proportion of participants who complete all planned assessments in both non-virtual reality (noVR) and virtual reality (VR) conditions. The predefined feasibility criterion is completion by at least 80% of participants.

At the end of the single assessment session on Day 1, after completion or discontinuation of the planned assessments.
Number of virtual reality-related technical issues
Tidsramme: From the start of virtual reality system setup to the end of the virtual reality assessments during the single assessment session on Day 1.

technical feasibility: assessed by the number and type of VR-related technical issues encountered

From the start of virtual reality system setup to the end of the virtual reality assessments during the single assessment session on Day 1.
Proportion of complete outcome measurements per test and condition
Tidsramme: Data recording during all planned tests in the virtual reality and non-virtual reality conditions within the single assessment session on Day 1.

data completeness: quantified as the proportion of complete outcome data per test and condition (criterion: ≥80% complete data)

Data recording during all planned tests in the virtual reality and non-virtual reality conditions within the single assessment session on Day 1.
Percentage increase in assessment time with virtual reality compared with no virtual reality
Tidsramme: From the start to the end of each assessment (mobility and balance assessments) in each condition (virtual reality and non-virtual reality) during the single assessment session on Day 1.

assessment burden: reflected by total assessment time, considered acceptable if VR assessments required no more than 20% additional time compared to noVR conditions

From the start to the end of each assessment (mobility and balance assessments) in each condition (virtual reality and non-virtual reality) during the single assessment session on Day 1.
Number of participants experiencing adverse events during assessment
Tidsramme: From the start of the assessment session until 15 minutes after its completion on Day 1, including both virtual reality and non-virtual reality assessments.

Number of participants experiencing at least one adverse event during the assessment session, including both virtual reality and non-virtual reality conditions, or within 15 minutes after its completion.

From the start of the assessment session until 15 minutes after its completion on Day 1, including both virtual reality and non-virtual reality assessments.
Virtual Reality Sickness Questionnaire scores (VRSQ)
Tidsramme: single session, Immediately after completion of the virtual reality session on Day 1.

The VRSQ is a modified version of the Simulator Sickness Questionnaire and consists of nine items assessing symptoms of VR-induced discomfort. These items are grouped into two subdomains: oculomotor discomfort (items 1-4) and disorientation (items 5-9). Each item is rated on a four-point Likert scale ranging from 0 ("not at all") to 3 ("severe"). Subscale scores are normalized and combined to yield a total VRSQ score, with higher scores indicating greater VR sickness.

single session, Immediately after completion of the virtual reality session on Day 1.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
iGroup Presence Questionnaire subscale scores
Tidsramme: single session, Immediately after completion of the virtual reality session on Day 1.

The IPQ assesses different dimensions of presence and consists of items grouped into four subscales: General Presence (GP), Spatial Presence (SP), Involvement (INV), and Experienced Realism (ER). Items are rated on a seven-point Likert scale ranging from 0 to 6, with higher scores indicating a stronger sense of presence within the virtual environment.

single session, Immediately after completion of the virtual reality session on Day 1.
Within-participant difference in Mini-BESTest total score between virtual reality and non-virtual reality conditions
Tidsramme: single session; During Mini-BESTest administration in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1.

The Mini-Balance Evaluation Systems Test (Mini-BESTest) is a standardized clinical assessment of dynamic balance and a shortened version of the Balance Evaluation Systems Test (BESTest). It consists of 14 items covering four balance domains: anticipatory postural adjustments (items 1-3), reactive postural control (items 4-6), sensory orientation (items 7-9), and dynamic gait (items 10-14) (A.3). Each item is scored on a three-level ordinal scale (0-2), resulting in a maximum total score of 28 points, with higher scores indicating better balance performance. For items requiring bilateral assessment (items 3 and 6), the lower score was retained.

single session; During Mini-BESTest administration in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1.
Within-participant difference in single-task and cognitive dual-task Timed Up and Go completion time between virtual reality and non-virtual reality conditions
Tidsramme: single session; During single-task and cognitive dual-task Timed Up and Go testing in both conditions (virtual reality and non-virtual reality) within the single assessment session on Day 1.

Participants are instructed to stand up from a chair, walk three meters at a safe and comfortable speed, cross a marked line on the floor, turn around, walk back to the chair, and sit down. The time required to complete the task was recorded in seconds. In addition to the standard single-task TUG, a cognitive dual-task version was administered. During the dual-task TUG, participants were asked to count backwards by threes from a randomly selected number between 20 and 100 while performing the motor task. Both single-task and dual-task TUG were performed under noVR and VR conditions, resulting in four TUG conditions in total.

single session; During single-task and cognitive dual-task Timed Up and Go testing in both conditions (virtual reality and non-virtual reality) within the single assessment session on Day 1.
Within-participant difference in comfortable walking speed between virtual reality and non-virtual reality conditions
Tidsramme: single session; During comfortable walking speed testing in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1

The 10-meter walk test was used to assess participants' walking speed. Participants started at the 0-meter (m) mark and walked to the 10 m mark. Timing was performed with a stop watch over the central 6 m, beginning 2 m after the start line and ending 2 m before the end line, to allow for acceleration and deceleration phases and to capture steady-state walking speed. Walking speed (m/s) was calculated by dividing the distance (6 m) by the recorded time (seconds). Two trials were performed at the participant's comfortable walking speed, followed by two trials at their fastest walking speed, according to standardized instructions.

For each speed condition, the two trials were averaged, and the resulting comfortable and fast gait speeds were documented in meters per second.

single session; During comfortable walking speed testing in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1
Within-participant difference in fast walking speed between virtual reality and non-virtual reality conditions
Tidsramme: single session; During fast walking speed testing in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1.

The 10-meter walk test was used to assess participants' walking speed. Participants started at the 0-meter (m) mark and walked to the 10 m mark. Timing was performed with a stop watch over the central 6 m, beginning 2 m after the start line and ending 2 m before the end line, to allow for acceleration and deceleration phases and to capture steady-state walking speed. Walking speed (m/s) was calculated by dividing the distance (6 m) by the recorded time (seconds). Two trials were performed at the participant's comfortable walking speed, followed by two trials at their fastest walking speed, according to standardized instructions.

For each speed condition, the two trials were averaged, and the resulting comfortable and fast gait speeds were documented in meters per second.

single session; During fast walking speed testing in each condition (virtual reality and non-virtual reality) within the single assessment session on Day 1.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Bart Jansen, PhD, ETRO, Vrije Universiteit Brussel

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. februar 2025

Primær fullføring (Faktiske)

28. februar 2025

Studiet fullført (Faktiske)

28. februar 2025

Datoer for studieregistrering

Først innsendt

19. oktober 2026

Først innsendt som oppfylte QC-kriteriene

5. november 2026

Først lagt ut (Faktiske)

12. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified individual participant data underlying the results reported in publications arising from this study will be made available by the corresponding author upon reasonable request following publication.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere